TELO Stock Overview
A pre-clinical stage biopharmaceutical company, focuses on developing pharmaceutical products for reversal of oxidative stress, cellular protection, and regulatory mechanism. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Telomir Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$4.12 |
| 52 Week High | US$9.39 |
| 52 Week Low | US$3.11 |
| Beta | 0 |
| 1 Month Change | -3.96% |
| 3 Month Change | -11.78% |
| 1 Year Change | -30.76% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -17.60% |
Recent News & Updates
Shareholder Returns
| TELO | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -9.3% | -0.3% | 0.7% |
| 1Y | -30.8% | 0.4% | 8.1% |
Return vs Industry: TELO underperformed the US Pharmaceuticals industry which returned 1% over the past year.
Return vs Market: TELO underperformed the US Market which returned 10% over the past year.
Price Volatility
| TELO volatility | |
|---|---|
| TELO Average Weekly Movement | 13.2% |
| Pharmaceuticals Industry Average Movement | 10.0% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 17.2% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: TELO's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: TELO's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2021 | 5 | Erez Aminov | telomirpharma.com |
Telomir Pharmaceuticals, Inc., a pre-clinical stage biopharmaceutical company, focuses on developing pharmaceutical products for reversal of oxidative stress, cellular protection, and regulatory mechanism. The company is developing Telomir 1, an oral small molecule metal ion regulator designed to extend telomere caps; maintain cellular balance; and combat oxidative stress that drives aging and disease progression. By modulating essential metal ions such as iron, and copper, Telomir-1 helps protect against age-related conditions, including Progeria, a rare genetic disorder that causes rapid aging in children; Wilson’s disease, a genetic disorder leading to toxic copper buildup in the body; and Age-related Macular Degeneration (AMD), as well as Type 2 Diabetes, cancer, and Alzheimer’s disease.
Telomir Pharmaceuticals, Inc. Fundamentals Summary
| TELO fundamental statistics | |
|---|---|
| Market cap | US$124.11m |
| Earnings (TTM) | -US$16.53m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-7.4x
P/E RatioIs TELO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TELO income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$16.53m |
| Earnings | -US$16.53m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.56 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 14.5% |
How did TELO perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/03/18 12:04 |
| End of Day Share Price | 2025/03/18 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Telomir Pharmaceuticals, Inc. is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Bradley Sorensen | Zacks Small-Cap Research |